SARS-CoV-2感染重症患者中产超广谱β-内酰胺酶肠杆菌相关呼吸机相关性肺炎:危险因素与预后
该研究为COVID-ICU多中心前瞻性国际队列(4929例COVID-19重症患者)的辅助分析,纳入591例首次肠杆菌相关VAP且耐药状态与结局数据完整的患者。主要致病菌为肠杆菌属(n=224)、大肠埃希菌(n=111)和肺炎克雷伯菌(n=104)。115例(19%)首次VAP为ESBL-E相关,8例(1%)为CRE相关。多因素分析显示非洲来源(OR 1.7 [1.07-2.71],p=0.02)、插管至VAP时间(OR 1.06 [1.02-1.09],p=0.002)、VAP当日PaO2/FiO2(OR 0.997 [0.994-0.999],p=0.04)及甲氧苄啶-磺胺甲噁唑暴露(OR 3.77 [1.15-12.4],p=0.03)与ESBL-E VAP相关。ESBL-E与非ESBL-E VAP患者脱机与死亡率无显著差异。
要点
- 591例COVID-19机械通气患者首次肠杆菌VAP中,115例(19%)为ESBL-E相关,8例(1%)为CRE相关。
- 多因素分析:非洲来源OR 1.7(95%CI 1.07-2.71,p=0.02)、插管至VAP时间OR 1.06(95%CI 1.02-1.09,p=0.002)与ESBL-E VAP独立相关。
- VAP当日PaO2/FiO2(OR 0.997,95%CI 0.994-0.999,p=0.04)及甲氧苄啶-磺胺甲噁唑暴露(OR 3.77,95%CI 1.15-12.4,p=0.03)亦与ESBL-E VAP相关。
- ESBL-E与非ESBL-E VAP患者脱机与死亡率无显著差异,首次肠杆菌VAP耐药状态未影响结局。
- ESBL-E VAP主要致病菌为肠杆菌属(n=40)、肺炎克雷伯菌(n=36)和大肠埃希菌(n=31)。
适用人群与场景
- COVID-ICU多中心前瞻性国际队列中4929例COVID-19重症患者,仅纳入首次肠杆菌相关VAP耐药状态(ESBL-E和/或CRE)与结局数据完整者,共591例。
研究设计与关键结果
- 研究类型:多中心前瞻性国际队列研究(COVID-ICU)的辅助分析,纳入591例首次肠杆菌相关VAP的COVID-19重症患者。
- 主要致病菌:肠杆菌属n=224、大肠埃希菌n=111、肺炎克雷伯菌n=104;115例(19%)首次VAP为ESBL-E相关,8例(1%)为CRE相关。
- ESBL-E VAP主要致病菌:肠杆菌属n=40、肺炎克雷伯菌n=36、大肠埃希菌n=31。
- 多因素分析:非洲来源(北非或撒哈拉以南非洲)OR 1.7(95%CI 1.07-2.71,p=0.02)、插管至VAP时间OR 1.06(95%CI 1.02-1.09,p=0.002)、VAP当日PaO2/FiO2 OR 0.997(95%CI 0.994-0.999,p=0.04)、甲氧苄啶-磺胺甲噁唑暴露OR 3.77(95%CI 1.15-12.4,p=0.03)与ESBL-E相关VAP相关。
- ESBL-E与非ESBL-E VAP患者脱机与死亡率无显著差异。
证据类型、等级与局限
- 证据类型:多中心前瞻性国际队列研究的辅助分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ESBL-E相关VAP在COVID-19重症患者中并不少见,识别出的危险因素中部分可改变,值得进一步研究。
- 作者结论:首次肠杆菌相关VAP的耐药状态对结局无影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-COV 2) and requiring mechanical ventilation suffer from a high incidence of ventilator associated pneumonia (VAP), mainly related to Enterobacterales. Data regarding extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E) VAP are scarce. We aimed to investigate risk factors and outcomes of ESBL-E related VAP among critically ill coronavirus infectious disease-19 (COVID-19) patients who developed Enterobacterales related VAP.
PATIENTS AND METHODS: We performed an ancillary analysis of a multicenter prospective international cohort study (COVID-ICU) that included 4929 COVID-19 critically ill patients. For the present analysis, only patients with complete data regarding resistance status of the first episode of Enterobacterales related VAP (ESBL-E and/or carbapenem-resistant Enterobacterales, CRE) and outcome were included.
RESULTS: We included 591 patients with Enterobacterales related VAP. The main causative species were Enterobacter sp (n = 224), E. coli (n = 111) and K. pneumoniae (n = 104). One hundred and fifteen patients (19%), developed a first ESBL-E related VAP, mostly related to Enterobacter sp (n = 40), K. pneumoniae (n = 36), and E. coli (n = 31). Eight patients (1%) developed CRE related VAP. In a multivariable analysis, African origin (North Africa or Sub-Saharan Africa) (OR 1.7 [1.07-2.71], p = 0.02), time between intubation and VAP (OR 1.06 [1.02-1.09], p = 0.002), PaO2/FiO2 ratio on the day of VAP (OR 0.997 [0.994-0.999], p = 0.04) and trimethoprim-sulfamethoxazole exposure (OR 3.77 [1.15-12.4], p = 0.03) were associated with ESBL-E related VAP. Weaning from mechanical ventilation and mortality did not significantly differ between ESBL-E and non ESBL-E VAP.
CONCLUSION: ESBL-related VAP in COVID-19 critically-ill patients was not infrequent. Several risk factors were identified, among which some are modifiable and deserve further investigation. There was no impact of resistance of the first Enterobacterales related episode of VAP on outcome.
参考来源
- Razazi K, Luyt CE, Voiriot G, et al. Ventilator-associated pneumonia related to extended-spectrum beta-lactamase producing Enterobacterales during severe acute respiratory syndrome coronavirus 2 infection: risk factors and prognosis. Crit Care. 2024. PMID: 38641851. doi:10.1186/s13054-024-04906-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。